Intelligence Feed event · Policy · 2026-10-21

    China NMPA grants Breakthrough Therapy Designation to Ascentage drug lisaftoclax

    Question

    China NMPA grants Breakthrough Therapy Designation to Ascentage drug lisaftoclax

    Direct answer

    Ascentage Pharma confirmed that the National Medical Products Administration (NMPA) in China granted Breakthrough Therapy Designation (BTD) to its Bcl-2 inhibitor lisaftoclax (APG-2575). The indication targets treatment-naive adult patients diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma when administered alongside acalabrutinib. Breakthrough status in China shortens regulatory review windows and expands clinical guidance from health authorities. The regulatory clearance bolsters Ascentage's commercialization pipeline in regional oncology markets while validating the therapeutic combination's clinical profile.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-21
    Published
    2026-10-21
    Revision
    1 · 2026-10-21

    Cite as: Market Ontology, “China NMPA grants Breakthrough Therapy Designation to Ascentage drug lisaftoclax”, revision 1, evidence through 2026-10-21. https://marketontology.com/market-events/2026-10-21/china-nmpa-grants-breakthrough-therapy-designation-to-ascentage-drug-lisaftoclax-322352

    POLICY
    China NMPA grants Breakthrough Therapy Designation to Ascentage drug lisaftoclax
    Ascentage Pharma confirmed that the National Medical Products Administration (NMPA) in China granted Breakthrough Therapy Designation (BTD) to its Bcl-2 inhibitor lisaftoclax (APG-2575). The indication targets treatment-naive adult patients diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma when administered alongside acalabrutinib. Breakthrough status in China shortens regulatory review windows and expands clinical guidance from health authorities. The regulatory clearance bolsters Ascentage's commercialization pipeline in regional oncology markets while validating the therapeutic combination's clinical profile.
    AAPG
    Impact
    73
    YESTERDAY
    SIG
    88%
    AAPG
    China NMPA grants Breakthrough Therapy Designation to Ascentage drug lisaftoclax
    Ascentage Pharma confirmed that the National Medical Products Administration (NMPA) in China granted Breakthrough Therapy Designation (BTD) to its Bcl-2 inhibitor lisaftoclax (APG-2575). The indication targets treatment-naive adult patients diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma when administered alongside acalabrutinib. Breakthrough status in China shortens regulatory review windows and expands clinical guidance from health authorities. The regulatory clearance bolsters Ascentage's commercialization pipeline in regional oncology markets while validating the therapeutic combination's clinical profile.
    → Regulatory breakthrough status accelerates review timelines with China's NMPA, pulling forward commercialization cash flows for AAPG's hematologic oncology portfolio.
    Impact
    Ascentage Pharma confirmed that the National Medical Products Administration (NMPA) in China granted Breakthrough Therapy Designation (BTD) to its Bcl-2 inhibitor lisaftoclax (APG-2575). The indication targets treatment-naive adult patients diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma when administered alongside acalabrutinib. Breakthrough status in China shortens regulatory review windows and expands clinical guidance from health authorities. The regulatory clearance bolsters Ascentage's commercialization pipeline in regional oncology markets while validating the therapeutic combination's clinical profile.
    Affected
    AAPG
    Transmission
    Regulatory breakthrough status accelerates review timelines with China's NMPA, pulling forward commercialization cash flows for AAPG's hematologic oncology portfolio.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    AAPGregulatory fast-track de-risking pipeline commercializationUp1-4wAscentage Pharma announced the NMPA granted Breakthrough Therapy Designation for lisaftoclax in CLL/SLL.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month